Efficacy and safety of catheter ablation as first-line therapy for the management of ventricular tachycardia.

ABSTRACT:

Background

Ventricular tachycardia (VT) is associated with significantly increased morbidity and mortality. Catheter ablation (CA) in line with an implantable cardioverter-defibrillator (ICD) is highly effective in VT management; however, it is unknown if CA should be considered as first-line therapy. The aim of this study is to verify the efficacy and safety of CA as first-line therapy for the first VT presentation (as adjunctive to ICD insertion), compared to initial ICD insertion and anti-arrhythmic drug (AAD) therapy.

Methods

Data from patients with the first presentation for VT from January 2017 to January 2021 was reviewed. Patients were classified as "ablation first" vs "ICD first" groups and compared the clinical outcomes between groups.

Results

One hundred an

SUBMITTER: Kotake Y 

PROVIDER: S-EPMC10547804 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature